Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Launched by HOSPITAL UNIVERSITARIO DR. JOSE E. GONZALEZ · Mar 18, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a medication called blinatumomab for patients with a type of cancer known as B-cell acute lymphoblastic leukemia (B-ALL). Specifically, the trial focuses on patients who have measurable residual disease (MRD), which means that even after treatment, some cancer cells are still present in the body. The goal is to see if a short, 7-day course of blinatumomab can help clear these remaining cancer cells before patients undergo a stem cell transplant, which is a common next step for those with MRD.
To participate in this trial, patients need to have Philadelphia chromosome-negative B-ALL and show detectable MRD while still in complete response to prior treatments. They should also be in reasonably good health, with a performance status score of 0 to 2, meaning they can carry out daily activities with little to no help. Throughout the trial, participants will receive the blinatumomab treatment and will be monitored for any side effects, as well as their overall survival and disease-free survival. It's important to note that some patients may not be eligible if they have certain health issues or have previously received blinatumomab. This trial is currently recruiting participants, so if you or a loved one might be interested, it could be a valuable opportunity to explore new treatment options.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
- • MRD detectable in complete response (above the limit of quantification according to FCM)
- • Performance status 0-2 on the ECOG scale
- • No prior organ damage
- • Having a potential related or unrelated donor
- Exclusion Criteria:
- • Performance status on the ECOG scale \>2
- • HCT-CI \>3 points
- • Patients who do not wish to participate in clinical study.
- • Active central nervous system infiltration (CNS3)
- • Active extramedullary disease
- • Having previously received blinatumomab
- • Absence of related or unrelated donors
About Hospital Universitario Dr. Jose E. Gonzalez
Hospital Universitario Dr. José E. González is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. Located in Monterrey, Mexico, the hospital is affiliated with the University of Nuevo León, fostering a collaborative environment that integrates education, patient care, and scientific inquiry. With a commitment to improving patient outcomes, the hospital actively conducts clinical trials across various medical disciplines, leveraging its state-of-the-art facilities and a multidisciplinary team of experts to explore new therapies and enhance treatment options for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Monterrey, Nuevo Leon, Mexico
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported